Following the intraduodenal installation of purified 125I-labeled human trypsin up to about 4--6% of the label was measured after 15--30 min in blood plasma and found to separate in a dextran-gel filtration system similar to purified human trypsin (-125I) after incubation with human serum. About 1% of the installed trypsin-(-125I)-dose was found already after 20 min in 100 ml of aspirated pancreatic secretion and later on also in the duodenal content. The results support the concept of the existence of an enteropancreatic circulation of trypsin also in man and explain in part the low to non-detectable levels of immunoreactive serum trypsin observed in patients with exocrine pancreatic insufficiency.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF01492985 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
Clin Cancer Res
December 2024
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can vary in aggressiveness, and this study aimed to confirm an automated test for serum chromogranin A (CgA) to help monitor these tumors' progression.
- The study involved 153 GEP-NET patients and assessed tumor progression using imaging alongside changes in CgA levels, with a specific threshold indicating tumor growth.
- Results showed the CgA test had high specificity (93.4%) and negative predictive value (84.3%), suggesting it could be a valuable tool alongside standard imaging methods for tracking GEP-NETs.
Circulating Regulatory T Cells: A Novel Marker Associated with Liver Metastasis and the Treatment Response of Transarterial Embolization in Gastroenteropancreatic Neuroendocrine Tumors.
Neuroendocrinology
September 2024
Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Introduction: The aim of this study was to investigate the role of circulating regulatory T cells (Tregs) as a novel marker associated with liver metastases and treatment response to transarterial embolization (TAE) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Methods: Circulating Tregs, defined as the CD4+CD25+CD127low/- population, were examined by flow cytometry in peripheral blood mononuclear cells from patients with GEP-NETs. Clinicopathological parameters, radiologic response, and hepatic progression-free survival (hPFS) data were collected.
Purpose: The immune environment represents a new, but little explored, tool for understanding neuroendocrine neoplasms (NENs) behavior. An immunosuppressed microenvironment is hypothesized to promote NENs progression. A missing profiling of circulating leukocyte and peripheral blood mononuclear cells (PBMCs) subpopulations would open new perspectives in the still limited diagnostic-therapeutic management of NENs.
View Article and Find Full Text PDFA Case of Primary Insular Ovarian Carcinoid Tumor with Hyperandrogenism and Carcinoid Heart Disease.
Am J Case Rep
October 2022
Division of Endocrinology and Metabolism, University of Alberta, Edmonton, Alberta, Canada.
BACKGROUND Carcinoid heart disease typically occurs in the presence of metastatic carcinoid tumor deposits in the liver, as vasoactive substances access the systemic circulation through the hepatic vein. Primary ovarian carcinoid tumors are rare neuroendocrine tumors, and can be associated with carcinoid syndrome and carcinoid heart disease. CASE REPORT We describe the case of a 40-year-old woman who presented with secondary amenorrhea, acne, hirsutism, and diarrhea.
View Article and Find Full Text PDFPrognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
J Clin Endocrinol Metab
March 2021
Department of Oncology, UCL Cancer Institute, University College London, London, UK.
Article Synopsis
- Circulating tumor cells (CTCs) are significant prognostic markers in neuroendocrine tumors (NETs), specifically pancreatic NETs (PanNETs) and midgut NETs.
- Research determined that a CTC threshold of 1 or more predicts progression-free survival (PFS) for PanNETs, while a threshold of 2 or more is optimal for midgut NETs, linked to higher odds of tumor progression and mortality.
- These findings provide clinically useful thresholds that can help guide patient stratification in treatment and research settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!